83 related articles for article (PubMed ID: 11006242)
1. Prospective determination of T-cell responses to S-antigen in Behçet's disease patients and controls.
de Smet MD; Dayan M
Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3480-4. PubMed ID: 11006242
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
3. Behçet's disease: clinical and immunological response to immunosuppressive therapy. A case report.
Rimon D; Lahat N; Nir E; Cohen L
Isr J Med Sci; 1985 Jan; 21(1):57-61. PubMed ID: 3156102
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
5. Endothelial cell activation and hypercoagulability in ocular Behçet's disease.
Probst K; Fijnheer R; Rothova A
Am J Ophthalmol; 2004 May; 137(5):850-7. PubMed ID: 15126149
[TBL] [Abstract][Full Text] [Related]
6. Cellular autoimmunity to retinal specific antigens in Behçet's disease.
Hamzaoui K; Mili Boussen E; Hamzaoui A; Ouertani A; Chabbou A; Ayed K
Tunis Med; 1998 Apr; 76(4):66-70. PubMed ID: 9739193
[No Abstract] [Full Text] [Related]
7. Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behçet uveitis.
Ahn JK; Park YG; Park SW; Yoon KC; Yu HG; Chung H
Ocul Immunol Inflamm; 2006 Oct; 14(5):267-75. PubMed ID: 17056460
[TBL] [Abstract][Full Text] [Related]
8. Expansion of gammadelta T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers.
Bank I; Duvdevani M; Livneh A
J Lab Clin Med; 2003 Jan; 141(1):33-40. PubMed ID: 12518166
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of T cell subsets in Behçet's syndrome using anti-T cell monoclonal antibodies.
Valesini G; Pivetti-Pezzi P; Mastrandrea F; Moncada A; Cuomo M; Natali PG
Clin Exp Immunol; 1985 Apr; 60(1):55-60. PubMed ID: 3874016
[TBL] [Abstract][Full Text] [Related]
10. Human S-antigen determinant recognition in uveitis.
de Smet MD; Bitar G; Mainigi S; Nussenblatt RB
Invest Ophthalmol Vis Sci; 2001 Dec; 42(13):3233-8. PubMed ID: 11726628
[TBL] [Abstract][Full Text] [Related]
11. Lymphocyte responses in juvenile chronic arthritis and Behçet's disease--cell number requirements and effects of glucocorticosteroid therapy.
de Vere-Tyndall A; Knight S; Burman S; Denman AM; Ansell BM
Clin Exp Immunol; 1982 Dec; 50(3):549-54. PubMed ID: 7165998
[TBL] [Abstract][Full Text] [Related]
12. [Immunosuppressive therapy of Behcet's syndrome. Long term follow-up evaluation (author's transl)].
Bonnet M
J Fr Ophtalmol; 1981; 4(6-7):455-64. PubMed ID: 7299062
[TBL] [Abstract][Full Text] [Related]
13. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation.
Freysdottir J; Hussain L; Farmer I; Lau SH; Fortune F
Oral Dis; 2006 May; 12(3):271-7. PubMed ID: 16700735
[TBL] [Abstract][Full Text] [Related]
14. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
15. Comparison of patients with Behçet's disease in the 1980s and 1990s.
Yoshida A; Kawashima H; Motoyama Y; Shibui H; Kaburaki T; Shimizu K; Ando K; Hijikata K; Izawa Y; Hayashi K; Numaga J; Fujino Y; Masuda K; Araie M
Ophthalmology; 2004 Apr; 111(4):810-5. PubMed ID: 15051217
[TBL] [Abstract][Full Text] [Related]
16. Does lowering hyperhomocysteinemia by folic acid beneficial for oculo-Behcet's disease? A pilot study.
Houman MH; Naffati H; Khanfir M; Ghannouchi M; Ben Ghorbel I; Lamloum M; El Matri L; Hamzaoui K; Jeddi A; Miled M; Fki M
Tunis Med; 2007 Jun; 85(6):450-3. PubMed ID: 17644895
[TBL] [Abstract][Full Text] [Related]
17. NF-kappaB protects Behçet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins.
Todaro M; Zerilli M; Triolo G; Iovino F; Patti M; Accardo-Palumbo A; di Gaudio F; Turco MC; Petrella A; de Maria R; Stassi G
Arthritis Rheum; 2005 Jul; 52(7):2179-91. PubMed ID: 15986355
[TBL] [Abstract][Full Text] [Related]
18. Behçet's disease: general concepts and recent advances.
Okada AA
Curr Opin Ophthalmol; 2006 Dec; 17(6):551-6. PubMed ID: 17065924
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
20. Increased entry of CD4+ T cells into the Th1 cytokine effector pathway during T-cell division following stimulation in Behcet's disease.
Koarada S; Haruta Y; Tada Y; Ushiyama O; Morito F; Ohta A; Nagasawa K
Rheumatology (Oxford); 2004 Jul; 43(7):843-51. PubMed ID: 15150429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
